Trial Profile

A phase IIa trial investigating the tolerability and pharmacodynamics of Vacc 4x (0.1 or 0.3 mg/dose) for the treatment of HIV-1 infections.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vacc-4x (Primary) ; Molgramostim
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
17 Oct 2013 The reboost study will be presented at the Global Health and Vaccination Research conference.
07 Aug 2013 Results from the first re-boost clinical trial of Vacc-4x, up to 7 years after the initial vaccination, have been accepted for publication in Vaccine, according to a Bionor Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com